Form 4: Lilly Endowment Inc. Sells 54,032 Shares of Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold 54,032 shares of common stock at an average price of $645.07 per share on January 29, 2024.

Summary

• Lilly Endowment Inc. sold 54,032 shares of Eli Lilly & Co. common stock on January 29, 2024.
• The shares were sold at a weighted average price of $645.07.
• The sale was executed in multiple transactions with prices ranging from $645.00 to $645.49 per share.
• Following the transaction, Lilly Endowment Inc. beneficially owns 99,488,598 shares of Eli Lilly & Co.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no inherent positive or negative sentiment.

Management Comments

• Diane M. Stenson, Vice President & Treasurer, signed the form on behalf of Lilly Endowment Inc.

Industry Context

This is a routine Form 4 filing, indicating a transaction by a major shareholder. Such filings are common and provide transparency into insider trading activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The transaction is similar to other large block trades by institutional investors, which are common in the market.
• The sale by Lilly Endowment Inc. is not unusual given their large holdings in Eli Lilly & Co.

Stakeholder Impact

• The sale may have a minor impact on the stock price, but is unlikely to be significant given the large number of shares outstanding.
• The transaction provides transparency to shareholders regarding insider activity.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, stock sale, share transaction, insider trading, beneficial ownership